Lancet Gastroenterology & Hepatology最新文献

{"title":"Sexual health and young people living with chronic hepatitis B: adopting a treatment as prevention framework","authors":"Suzanne J Block, Peter Daniel Block, Camilla S Graham, Mark Sulkowski, Su Wang, Thomas Tu, Chari Cohen","doi":"10.1016/s2468-1253(25)00123-2","DOIUrl":"https://doi.org/10.1016/s2468-1253(25)00123-2","url":null,"abstract":"No Abstract","PeriodicalId":56028,"journal":{"name":"Lancet Gastroenterology & Hepatology","volume":"11 1","pages":"609-612"},"PeriodicalIF":35.7,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144218960","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hypovolaemic phlebotomy and bloodless liver surgery","authors":"Dimitrios Moris, Piyush Gupta, Pejman Radkani, Brent Gilmore, Lorenzo De Marchi","doi":"10.1016/s2468-1253(24)00436-9","DOIUrl":"https://doi.org/10.1016/s2468-1253(24)00436-9","url":null,"abstract":"No Abstract","PeriodicalId":56028,"journal":{"name":"Lancet Gastroenterology & Hepatology","volume":"32 1","pages":"613"},"PeriodicalIF":35.7,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144218962","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reservations for Nine: A Doctor's Family Confronts Cancer","authors":"Hollie Sherwood-Martin","doi":"10.1016/s2468-1253(25)00170-0","DOIUrl":"https://doi.org/10.1016/s2468-1253(25)00170-0","url":null,"abstract":"No Abstract","PeriodicalId":56028,"journal":{"name":"Lancet Gastroenterology & Hepatology","volume":"100 1","pages":"621"},"PeriodicalIF":35.7,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144218971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Julia Mayerle: circling around the pancreas","authors":"Heather Van Epps","doi":"10.1016/s2468-1253(25)00169-4","DOIUrl":"https://doi.org/10.1016/s2468-1253(25)00169-4","url":null,"abstract":"No Abstract","PeriodicalId":56028,"journal":{"name":"Lancet Gastroenterology & Hepatology","volume":"11 1","pages":"620"},"PeriodicalIF":35.7,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144218864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of [18F]FDG and [18F]FCH PET-CT in hepatocellular carcinoma with cirrhosis","authors":"Hanwen Yang, Simeng Lei, Zhili Ji","doi":"10.1016/s2468-1253(25)00091-3","DOIUrl":"https://doi.org/10.1016/s2468-1253(25)00091-3","url":null,"abstract":"No Abstract","PeriodicalId":56028,"journal":{"name":"Lancet Gastroenterology & Hepatology","volume":"49 1","pages":"614"},"PeriodicalIF":35.7,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144218963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"India's continued response to tackling metabolic disorders and non-communicable diseases","authors":"Manya Prasad, Bharat Bhushan Rewari, Shiv Kumar Sarin","doi":"10.1016/s2468-1253(25)00131-1","DOIUrl":"https://doi.org/10.1016/s2468-1253(25)00131-1","url":null,"abstract":"No Abstract","PeriodicalId":56028,"journal":{"name":"Lancet Gastroenterology & Hepatology","volume":"1 1","pages":"616-617"},"PeriodicalIF":35.7,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144218966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Alcohol and health: time for Europe to sober up","authors":"","doi":"10.1016/s2468-1253(25)00165-7","DOIUrl":"https://doi.org/10.1016/s2468-1253(25)00165-7","url":null,"abstract":"No Abstract","PeriodicalId":56028,"journal":{"name":"Lancet Gastroenterology & Hepatology","volume":"11 1","pages":"605"},"PeriodicalIF":35.7,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144218961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Digestive Disease Week 2025","authors":"Bethany Gomersall","doi":"10.1016/s2468-1253(25)00167-0","DOIUrl":"https://doi.org/10.1016/s2468-1253(25)00167-0","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>AGMB-129 for fibrostenotic Crohn's disease</h2>Interim results from the phase 2a, randomised STENOVA trial presented by Florian Rieder (Cleveland, OH, USA) show that AGMB-129—an oral, gastrointestinal-restricted, small molecule ALK5 (TGF-β receptor type-1) inhibitor—is safe in patients with fibrostenotic Crohn's disease. Adults with symptomatic fibrostenotic Crohn's disease and at least one confirmed ileal stricture were randomly assigned (1:1:1) to receive AGMB-129 200 mg twice per day, AGMB-129 100 mg once per day, or placebo for 12</section></section><section><section><h2>EBX-102-02 in IBS-C</h2>EBX-102-02, an oral full-spectrum microbiome drug, was safe, well tolerated, and improved symptoms in patients with constipation-predominant irritable bowel syndrome (IBS-C), according to the randomised, double-blind, placebo-controlled, phase 2 TRIUMPH trial presented by Anthony Hobson (London, UK). 62 participants with Rome IV IBS-C (and IBS-SSS ≥175) were randomly assigned (2:1) to receive two doses (of eight capsules) of EBX-102-02 or placebo, 1 week apart. Between baseline and week 7, mean</section></section><section><section><h2>Dupilumab for eosinophilic gastritis</h2>In the randomised, double-blind, placebo-controlled, phase 2 DEGAS trial presented by Nirmala P Gonsalves (Chicago, IL, USA), dupilumab—a dual IL-4 and IL-13 blocker—was safe and efficacious in patients with eosinophilic gastritis. 41 adults and adolescents (aged 12–70 years) with symptomatic, histologically active eosinophilic gastritis (≥30 eosinophils per high-power field [hpf] in ≥5 hpfs in the gastric antrum, body, or both) were randomly assigned (1:1) to receive either placebo or</section></section><section><section><h2>Linaclotide in children with IBS-C</h2>Already FDA-approved for adults, linaclotide showed safety and preliminary efficacy in children with IBS-C in a double-blind, phase 3 study presented by Jeffrey Hyams (Hartford, CT, USA). Children aged 7–17 years with Rome III IBS-C were randomly assigned to linaclotide 145 μg or 290 μg daily for 12 weeks. The primary endpoint, based on twice-daily eDiary entries, was the proportion of participants who had a reduction in abdominal pain of at least 30% and an increase of at least two spontaneous</section></section>","PeriodicalId":56028,"journal":{"name":"Lancet Gastroenterology & Hepatology","volume":"11 1","pages":"618"},"PeriodicalIF":35.7,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144218969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"EASL Congress 2025","authors":"Hugh Thomas","doi":"10.1016/s2468-1253(25)00168-2","DOIUrl":"https://doi.org/10.1016/s2468-1253(25)00168-2","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Undiagnosed liver fibrosis in Europe</h2>Undiagnosed liver fibrosis is common in the European adult population, primarily driven by metabolic risk factors and alcohol consumption, according to the prospective LIVERSCREEN cohort study. Isabel Graupera and colleagues enrolled 30 541 adults older than 40 years without known liver disease from nine European countries. Liver fibrosis was assessed by liver stiffness measurement (LSM) using vibration-controlled transient elastography, with the primary outcome being the prevalence of LSM of 8</section></section><section><section><h2>Long-term albumin in cirrhosis</h2>Long-term albumin (LTA) therapy did not significantly improve 1-year transplantation-free survival in patients with cirrhosis, acute decompensation, and existing or previous ascites, according to the PRECIOSA trial. Jacqueline G O’Leary and colleagues randomly assigned 410 patients to receive standard medical treatment plus LTA (1·5 g/kg every 10 days for up to 12 months; n=203) or standard medical treatment alone (n=207). At 1 year, transplantation-free survival (the primary endpoint) was</section></section><section><section><h2>Resmetirom in MASH cirrhosis</h2>2 years of treatment with resmetirom improved liver stiffness and reduced portal hypertension risk in patients with compensated cirrhosis related to metabolic dysfunction-associated steatohepatitis, according to an open-label trial analysis. Naim Alkhouri and colleagues assessed 122 patients with Child–Pugh A MASH cirrhosis who were treated with 80 mg resmetirom daily for up to 2 years. The primary endpoint was safety and tolerability: 113 (93%) patients completed 2 years of treatment in the</section></section><section><section><h2>Norucholic acid in primary sclerosing cholangitis</h2>Norucholic acid treatment for 96 weeks improved biochemical markers and reduced fibrosis progression in patients with primary sclerosing cholangitis (PSC), according to a pivotal phase 3 trial. Michael Trauner and colleagues randomly assigned (2:1) 301 adult patients with PSC and an alkaline phosphatase (ALP) greater than 1.5 times the upper limit of normal (ULN) to receive 1500 mg norucholic acid once daily (n=205) or placebo (n=96). The combined primary endpoint at 96 weeks was partial</section></section>","PeriodicalId":56028,"journal":{"name":"Lancet Gastroenterology & Hepatology","volume":"61 1","pages":"619"},"PeriodicalIF":35.7,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144218970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of [18F]FDG and [18F]FCH PET-CT in hepatocellular carcinoma with cirrhosis – Author's reply","authors":"Jean-Charles Nault","doi":"10.1016/s2468-1253(25)00155-4","DOIUrl":"https://doi.org/10.1016/s2468-1253(25)00155-4","url":null,"abstract":"No Abstract","PeriodicalId":56028,"journal":{"name":"Lancet Gastroenterology & Hepatology","volume":"331 1","pages":"614-615"},"PeriodicalIF":35.7,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144218964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}